ÂÜÀòÂÒÂ×

Mark Dizon is Frontier Medicines' General Counsel. Prior to joining Frontier, Mr. Dizon was the Assistant General Counsel and Chief Compliance Officer at BeiGene, Ltd., and was responsible for global compliance, healthcare (R&D and commercial) law, data privacy, employment law, enterprise risk management, and litigation. While at BeiGene, he supported 30+ clinical studies globally, resulting in more than a dozen regulatory approvals for BeiGene products, including tislelizumab (anti-PD-1 monoclonal antibody, pamiparib (PARP inhibitor), and zanubrutinib (BTK inhibitor). In addition, he collaborated closely with BeiGene research and development, commercial and business development teams, as well as external business partners, on multiple joint development and co-promotion collaborations, including partnerships with Celgene/BMS, Amgen and Novartis generating more than $3 billion in value for BeiGene. Prior to BeiGene, Mr. Dizon served in various legal leadership roles at both large pharmaceuticals and small biotechs -- such as Chiron, Novartis, Affymax, Actelion, Relypsa and Prothena Biosciences -- where he was able to help bring new therapies to market for patients with various cardiovascular, chronic kidney, lung and cancer conditions. Mr. Dizon obtained his J.D. from the University of California Hastings College of Law and completed his undergraduate studies at the University of California at Berkeley.